Le Lézard
Classified in: Health
Subjects: PER, SCZ

CareRx Announces Retirement of Dr. Jack Shevel as Director


TORONTO, Dec. 7, 2022 /CNW/ - CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that Dr. Jack Shevel, a director and Chairman Emeritus of CareRx, will retire from the Company's Board of Directors effective December 31, 2022.

Dr. Shevel was a founding shareholder of Centric Health, the predecessor entity to CareRx, and has been a director and significant shareholder of the Company since 2009. Dr. Shevel has previously served as President and Chief Executive Officer of the Company, and was Chairman of the Board from 2010 to 2018 before becoming Chairman Emeritus.

"Jack has made significant contributions to the Company over the past 13 years," said Kevin Dalton, Chairman of CareRx. "He was instrumental in driving the strategic direction of the Company over the first several years of his involvement and has contributed deep industry expertise throughout his tenure. On behalf of the Board of Directors, I want to thank Jack for his contributions to the Company and wish him the best of luck in his future endeavors."

Reflecting on his many years with CareRx, Dr. Shevel remarked, "After serving over 13 years on the Board of Directors, I feel this is the right time to retire. It has been a pleasure to have been part of this exceptional organization that continues to play an important role in healthcare delivery in Canada, and I am confident that management and the entire CareRx team will continue to execute on a long-term strategy that will create value for all stakeholders".

About CareRx Corporation

CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 95,000 residents in over 1,600 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

SOURCE CareRx Corporation


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: